/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
$0.76
+$0.01 (+1.32%)
EOD Sep 18, 2026
ROIC dropped from -62.40% to -65.86%, capital efficiency is deteriorating. Negative free cash flow of -$13M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$12M
▲ +2.8% YoY
Op. Margin
—
ROIC
-40.41%
▼ -3.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$12M
▲ +5.0% YoY
Op. Cash Flow (TTM)
-$12M
▲ +4.9% YoY
Net Debt
-$41M
Net Cash Position
Cash & Equiv.
$41M
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.